FR09C0037I1 - - Google Patents

Info

Publication number
FR09C0037I1
FR09C0037I1 FR09C0037C FR09C0037I1 FR 09C0037 I1 FR09C0037 I1 FR 09C0037I1 FR 09C0037 C FR09C0037 C FR 09C0037C FR 09C0037 I1 FR09C0037 I1 FR 09C0037I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR09C0037I1 publication Critical patent/FR09C0037I1/fr
Application granted granted Critical
Publication of FR09C0037I2 publication Critical patent/FR09C0037I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR09C0037C 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise Active FR09C0037I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042002 1997-08-28
KR19970042001 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
FR09C0037I1 true FR09C0037I1 (cg-RX-API-DMAC10.html) 2009-09-25
FR09C0037I2 FR09C0037I2 (fr) 2021-11-05

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0037C Active FR09C0037I2 (fr) 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise

Country Status (15)

Country Link
US (1) US6309650B1 (cg-RX-API-DMAC10.html)
EP (2) EP1604685B1 (cg-RX-API-DMAC10.html)
JP (1) JP4161017B2 (cg-RX-API-DMAC10.html)
KR (1) KR100314404B1 (cg-RX-API-DMAC10.html)
CN (1) CN1142271C (cg-RX-API-DMAC10.html)
AU (1) AU748730B2 (cg-RX-API-DMAC10.html)
CA (1) CA2301000C (cg-RX-API-DMAC10.html)
DE (2) DE69837211T2 (cg-RX-API-DMAC10.html)
DK (2) DK1025209T3 (cg-RX-API-DMAC10.html)
ES (2) ES2281929T3 (cg-RX-API-DMAC10.html)
FR (1) FR09C0037I2 (cg-RX-API-DMAC10.html)
MY (1) MY129773A (cg-RX-API-DMAC10.html)
NL (1) NL300391I2 (cg-RX-API-DMAC10.html)
NZ (1) NZ503522A (cg-RX-API-DMAC10.html)
WO (1) WO1999011762A1 (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
EP1057889B1 (en) * 1998-10-05 2009-04-22 The Research Foundation for Microbial Diseases of Osaka University Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
ATE474041T1 (de) * 1999-04-22 2010-07-15 Us Agriculture Auf dem isolat ja-142 basierender impfstoff gegen das reproduktive-und-respiratorische syndrom beim schwein
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
WO2003002069A2 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
WO2005080556A2 (en) * 2004-02-23 2005-09-01 Crucell Holland B.V. Virus purification methods
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈-丁二烯-苯乙烯共聚物及其回收方法
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
US8591916B2 (en) * 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
MY173418A (en) * 2007-12-26 2020-01-23 Daiichi Sankyo Co Ltd Method of producing japanese encephalitis avccines stably storable over long time and use of the vaccine
EP2298344B1 (en) * 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Use of inactivated japanese encephalitis virus particle as adjuvant
KR101622738B1 (ko) * 2008-07-30 2016-05-19 히사미쓰 세이야꾸 가부시키가이샤 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
DK3106176T3 (en) 2011-12-06 2018-01-08 Valneva Austria Gmbh ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
IN2013CH04135A (cg-RX-API-DMAC10.html) * 2013-09-14 2015-08-14 Bharat Biotech Int Ltd
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
DK3393510T5 (da) 2015-12-23 2024-09-30 Valneva Austria Gmbh Zikavirusvaccine
KR102405736B1 (ko) * 2016-01-15 2022-06-07 케이엠 바이올로직스 가부시키가이샤 고정화 바이러스 입자를 포함하는 백신
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
AU2018337681B2 (en) 2017-09-21 2025-04-10 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus chikv-delta5nsp3
CN111615397B (zh) 2017-11-03 2024-09-13 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
MX2020005554A (es) 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
EP3845639A4 (en) * 2018-08-27 2022-05-11 Mican Technologies Inc. PROCEDURE FOR EVALUATION OF ANTIINFECTIVES, VACCINES ETC. USING IMMORTALIZED MONOCYTIC CELLS AND INDUCED CELLS
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
JP2023515908A (ja) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング CpGアジュバント化SARS-CoV-2ウイルスワクチン
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化SARS—CoV—2病毒疫苗
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
US20250027057A1 (en) * 2022-04-20 2025-01-23 Korea National Institute Of Health High-titer japanese encephalitis virus genotype 5 and uses thereof
EP4652265A1 (en) 2023-01-18 2025-11-26 Valneva Austria GmbH Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
DK1025209T3 (da) 2007-06-25
ES2281929T3 (es) 2007-10-01
EP1025209A1 (en) 2000-08-09
EP1604685A3 (en) 2006-07-05
AU9004798A (en) 1999-03-22
CN1142271C (zh) 2004-03-17
NZ503522A (en) 2001-06-29
MY129773A (en) 2007-04-30
KR100314404B1 (ko) 2002-10-12
WO1999011762A1 (en) 1999-03-11
NL300391I2 (nl) 2009-11-02
CN1272879A (zh) 2000-11-08
DE122009000037I2 (de) 2011-06-16
JP2001514844A (ja) 2001-09-18
CA2301000A1 (en) 1999-03-11
DK1604685T3 (da) 2012-06-18
EP1604685A2 (en) 2005-12-14
DE122009000037I1 (de) 2009-11-05
NL300391I1 (nl) 2009-08-03
KR19990023955A (ko) 1999-03-25
US6309650B1 (en) 2001-10-30
JP4161017B2 (ja) 2008-10-08
ES2382946T3 (es) 2012-06-14
FR09C0037I2 (fr) 2021-11-05
EP1604685B1 (en) 2012-02-22
DE69837211T2 (de) 2007-12-06
EP1025209B1 (en) 2007-02-28
AU748730B2 (en) 2002-06-13
CA2301000C (en) 2003-07-08
DE69837211D1 (de) 2007-04-12

Similar Documents

Publication Publication Date Title
BE2018C032I2 (cg-RX-API-DMAC10.html)
FR07C0057I1 (cg-RX-API-DMAC10.html)
FR09C0037I1 (cg-RX-API-DMAC10.html)
CH0944937H2 (cg-RX-API-DMAC10.html)
IN190268B (cg-RX-API-DMAC10.html)
ITMI971105A0 (cg-RX-API-DMAC10.html)
ITMI970397V0 (cg-RX-API-DMAC10.html)
ITRM970369A0 (cg-RX-API-DMAC10.html)
IN182159B (cg-RX-API-DMAC10.html)
IN189588B (cg-RX-API-DMAC10.html)
IN190391B (cg-RX-API-DMAC10.html)
IN185786B (cg-RX-API-DMAC10.html)
ITMI970351V0 (cg-RX-API-DMAC10.html)
ITFI970057A0 (cg-RX-API-DMAC10.html)
CN3054099S (cg-RX-API-DMAC10.html)
CN3058138S (cg-RX-API-DMAC10.html)
CN3055123S (cg-RX-API-DMAC10.html)
CN3054902S (cg-RX-API-DMAC10.html)
CN3054602S (cg-RX-API-DMAC10.html)
CN3055179S (cg-RX-API-DMAC10.html)
CN3054556S (cg-RX-API-DMAC10.html)
CN3055389S (cg-RX-API-DMAC10.html)
CN3057229S (cg-RX-API-DMAC10.html)
CN3054162S (cg-RX-API-DMAC10.html)
CN3055471S (cg-RX-API-DMAC10.html)